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Abstract
Primary intracranial malignant melanoma (PIMM) are rare
brain tumours; more infrequent than melanomas
metastasizing to the brain or those extending to the brain
from adjacent structures such as the orbit. Complete
surgical excision with adjuvant chemotherapy and
radiation remains the mainstay of treatment. Herein, we
have reviewed the literature to find the treatment
modalities for PIMMs that can lead to longer overall
survivals and better patient outcomes.
Keywords: Malignant Melanoma, Primary Intracranial
Melanoma, Brain Tumour.
Introduction
Primary Intracranial Malignant Melanoma (PIMM)is an
extremely rare tumour, accounting for not less than 0.1%
of all brain tumours.1-3 It may be argued that most PIMM
may actually be metastatic, as at times the primary lesion
may  be difficult to locate. In most cases, they stain
positively for the S100 protein, and malignant melanoma
antibody (HMB-45).2 Depending upon their pathological
behaviour, they can be divided into 2 subtypes; diffuse,
and solitary, nodular lesions.3,4 While few studies have
shown improvements in the overall survival with surgical
resec tion and adjuvant  radiotherapy  a nd/or
chemotherapy, a standard treatment protocol for PIMM
is yet to be established. This can be contributed to the
rarity of the tumour, difficult pre-operative diagnosis and
a  rather  poor prognosis  despite treatment.
Review of Evidence
Recent studies show an improvement in the survival
potential of metastatic malignant melanoma (MMM)
patients through targeted therapies against mutated BRAF
proteins, and immunotherapeutic agents; the interleukins
and anti-cytotoxic T-lymphocyte antigen 4.2,5 The use of
several chemotherapeutic agents, including dacarbazine,
temozolomide, BRAF inhibitors such as vemurafenib, and
intrathecal methotrexate have also been reported, without,
however, any reports of an increased overall survival with
any of them.2 Paul et al., reported a significant reduction
in CNS relapse in the temozolomide group compared with
the dacarbazine group at 19-month follow-up.6 However,
its utility in the chemo resistant PIMM remains
questionable. To the best of our knowledge, no large
cohort studies or randomized controlled trials have been
performed on the subject, with only a few case reports
and series existing in the literature.
Nakagawa et al., reported three decades ago, a survival
of 9.5 years in a patient with a solitary PIMM, having
undergone three surgical resections and an adjuvant
chemotherapy regimen composed of vincristine, methyl-
CCNU, and no-cardia CWS (cell wall skeleton).7 Another
case report by Onal et al., shared a surprisingly long overall
survival of 17 years in a patient after having undergone
gross total resection of the solitary tumour, external beam
irradiation to the tumour bed, and adjuvant chemotherapy
with methyl-CCNU.8 Martin et al., also published a case of
a patient who underwent sub-total resection of a PIMM
in the pineal region, followed by stereotactic radiosurgery
(SRS). Follow-up scans at 12 and 52 weeks respectively,
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Figure-1:  Axial section of MRI brain T1-weighted image showing heterogenous
hyperintense signals in the left parieto-occipital region with mass
effect. The lesion was reported as Malignant Melanoma on
histopathology.
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revealed no recurrence or progression of disease. However,
at 63 weeks, the patient developed somnolence and gait
ataxia, secondary to a tumour bleed. The patient later
died at 65 weeks post-surgery, exhibiting a rapid
progression of disease despite a favourable course over
more than a year.9
Wang et al., retrospectively analyzed eight patients with
PIMM in their series.4 Gross total and sub-total surgical
resection was achieved in six and two patients,
respectively. Postoperatively, seven patients showed
improvement in symptoms, while one remained the same
at the time of discharge. Six patients received radiation
after surgery. The mean follow-up period was 13.8 months,
during which, three patients died, and one showed
recurrence at 16 months. Four patients were alive by the
end of the study period with no progression in disease.
Based on their experience and review of literature, they
suggested a treatment protocol dependent upon the
location and size of the tumour, the number of lesions,
the overall state of systemic disease and symptoms of
patients at the time of diagnosis. For patients with a single
primary intracranial malignant melanoma lesion greater
than 3 cm in diameter that presented with significant
mass effects or CSF obstruction, microsurgical excision
was recommended first, followed by local radiation
therapy (such as SRS) or whole brain radiation therapy
(WBRT). However, in patients with a lesion less than 3 cm
in diameter, or located deep in the brain, local radiation
therapy (SRS or Gamma-knife) or auxiliary WBRT were
recommended.4
In a retrospective cohort of 24 patients Byun et al.,
compared the management of PIMM with metastatic
intracranial malignant melanoma and concluded that
maximal safe resection plus adjuvant radiation and
chemotherapy for intracranial malignant melanomas as
first line treatment options, improved prognosis and
prevented disease relapse.2 The overall survival rates of
PIMM, independent of treatment modalities applied, were
100% at 6 months, reducing to 25% at 18 months of follow
up. The progression free survival rate of PIMM at 3 months
was 66.7%, going down to 16.7% at 12 months.2
Arai et al., reviewed 49 patients from the literature and
concluded gross total surgical resection to be the most
promising intervention for longer survival.10 In their study,
42 patients underwent surgical resection, with the mean
overall survival for gross total resection being better than
that of surgeries leaving behind residual tumour (>22
months vs. 12 months). Nine patients received adjuvant
chemotherapy; 6 patients with temozolomide and 3
patients with a variety of regimens. Eighteen patients
underwent post-operative radiation therapy, with two
patients from different studies showing prolonged overall
survival. However, they found no significant difference in
overall survival, with or without adjuvant therapy.10
Figure-2:  Axial section of MRI brain T1-weighted post-contrast image of the
same patient, showing heterogenous hyperintense signals and subtle
contrast enhancement.
Figure-3:  Axial section of MRI brain T2-weighted image of the same patient,
showing heterogenous hypointense signals and significant per-
lesional edema.
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In the most recent, and perhaps the most exhaustive study
on the topic, involving 115 patients with PIMM, 15 from
the author's own center and a 100 from the literature, Li
et al., reported an overall survival rate of 62.8% at 6 months,
falling to 17.2% at 5 years, with an estimated median
survival time (EMST) of 12 months.3 The EMST was better
in patients with a solitary-type lesion (13 months) as
compared to those with a diffuse type lesion (5 months).
In their review of all patients, those receiving gross total
resection with adjuvant radiation therapy and/or
chemotherapy, had significantly higher 1-year and 5-year
overall survival rates (73.0% and 40.1%, respectively) and
a longer EMST (53 months) than patients who underwent
gross total resection alone (20.5 months) or radiation
and/or chemotherapy without resection (13.0 months).
They also suggested adding targeted therapy to the
treatment protocol, given its efficacy in metastatic
intracranial melanomas.3
Conclusion
We conclude that for PIMM, whenever feasible, gross total
resection of lesion remains the strategy of choice. Adjuvant
radiation and chemotherapy have also been shown to
prevent disease progression and relapse. Immunotherapy
and targeted therapies may have prospects for future
management of the disease.
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